STOCK TITAN

Neuronetics (STIM) Stock News, Apr-May 2023

STIM NASDAQ

Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.

News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.27%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
Rhea-AI Summary

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, a medical technology company focused on neurohealth, announced it will release its first quarter 2023 financial and operating results before the market opens on May 9, 2023. A conference call is scheduled for the same day at 8:30 a.m. Eastern Time to discuss these results.

The call will be accessible via a live webcast and participants can register for phone access in advance. Neuronetics emphasizes the importance of mental health, offering its NeuroStar Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD) and other conditions. NeuroStar has delivered over 5.3 million treatments and is backed by extensive clinical data, making it a leader in transcranial magnetic stimulation (TMS) therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences earnings
-
Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) announced that BlueCross BlueShield of Mississippi will allow non-physician practitioners to prescribe Transcranial Magnetic Stimulation (TMS) for treating major depressive disorder (MDD). This policy change aims to enhance patient access to NeuroStar therapy, a non-invasive treatment effective for drug-resistant depression.

With over 855,716 covered lives in Mississippi, the policy lowers the medication trial requirement from four to two before TMS treatment. Neuronetics emphasizes the importance of mental health and has delivered over 5.3 million NeuroStar treatments, supporting its leadership in the TMS sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary

Neuronetics (NASDAQ: STIM) has announced its fifth FDA clearance in under two years, enhancing the NeuroStar system with improved Wi-Fi capabilities. This advancement allows providers greater flexibility in system placement and offers expanded connectivity options for TrakStar, facilitating better operational efficiency.

Dr. Kenneth Pages, a NeuroStar provider, expressed excitement over the new feature, stating it enables a focus on patient care while simplifying operations. The update is part of a broader initiative, which includes software releases for the TrakStar Patient Data Management System and a new educational campaign aimed at NeuroStar providers. The company continues to focus on improving neurohealth treatment options, underscoring its commitment to investing in technology that enhances patient and provider experiences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) announced a new credit facility with SLR Capital Partners, allowing borrowings up to $60 million. This includes a Term A Loan of $35 million fully drawn prior to the amendment and additional loans totaling $25 million. The facility's maturity is set for March 29, 2028. The company aims for cash flow breakeven by 2024. Furthermore, Neuronetics provided Greenbrook TMS with a $6 million promissory note, part of a revised device supply agreement. The note bears interest of 7.65% and matures on March 31, 2027. Both agreements are intended to strengthen Neuronetics' balance sheet and support growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none

FAQ

What is the current stock price of Neuronetics (STIM)?

Neuronetics (STIM) last closed at $1.28.

What is the market cap of Neuronetics (STIM)?

The market cap of Neuronetics (STIM) is approximately $123.5M.